Needham analyst Serge Belanger has maintained their bullish stance on EOLS stock, giving a Buy rating today.
Serge Belanger has given his Buy rating due to a combination of factors that highlight Evolus’s promising outlook. The company’s recent financial disclosures and strategic updates suggest strong growth potential, particularly with the expansion of its product line. Evolus’s Jeuveau product continues to show robust growth, and the anticipated launch of the Evolysse fillers, following recent FDA approvals, is expected to significantly contribute to the company’s revenue targets for 2025.
Belanger’s confidence is further supported by Evolus’s guidance for substantial year-over-year revenue growth and non-GAAP operating income. The successful launch of new products in early 2025 is seen as a pivotal moment for the company, reinforcing the Buy rating with a price target of $22. This strategic positioning and expected market performance underpin the positive outlook for Evolus’s stock.
In another report released today, Barclays also maintained a Buy rating on the stock with a $25.00 price target.